| Ytd | 78.57% | |
| 1y | 236.00% |
| Open | 75.59 | Prev Close | 74.86 | Low | 74.02 | High | 75.63 | Mkt Cap | 2.17B |
| Vol | 317.04K | Avg Vol | 980.42K | EPS | -8.40 | P/E | -8.99 | Forward P/E | -6.44 |
| Beta | 1.16 | Short Ratio | 5.48 | Inst. Own | 92.05% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 66.59 | 200-d Avg | 63.49 | 1yr Est | 153.22 |
NKTR News
NEW YORK, Aug. 11, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is inves
Nektar Therapeutics (NASDAQ: NKTR - Get Free Report) will likely be releasing its Q2 2026 results af
SAN FRANCISCO, July 28, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its fi
The average of price targets set by Wall Street analysts indicates a potential upside of 104.1% in N
Nektar Therapeutics (NASDAQ: NKTR - Get Free Report) shares gapped up before the market opened on Fr
SAN FRANCISCO, July 24, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that
Nektar begins two phase III ZENITH AD studies of rezpeg for moderate-to-severe atopic dermatitis, wi
Canaccord Genuity analyst Edward Nash initiates coverage on Nektar Therapeutics (NASDAQ:NKTR) wit
This whale alert can help traders discover the next big trading opportunities. Whales are entities w
Two global registrational Phase 3 trials initiated in ZENITH AD programPhase 3 program based upon cl
Two global registrational Phase 3 trials initiated in ZENITH AD program Phase 3 program based upon c
SAN FRANCISCO, June 26, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that
Robin sold 20,000 shares over two days for a transaction value of $1.22 million at a weighted averag
Big pharma's appetite for clinical-stage biotech is back. The pending acquisition of Apogee Therapeu
SAN FRANCISCO, June 3, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that,
SAN FRANCISCO, May 27, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that
This biotech firm develops immunotherapies for cancer and autoimmune diseases, with several candidat
Nektar Therapeutics NASDAQ: NKTR outlined plans to advance its lead regulatory T-cell (Treg) therapy
NKTR misses Q1 earnings and revenue estimates. Investor focus stays on rezpeg as the company advance
Nektar Therapeutics (NKTR) Q1 2026 Earnings Call Transcript
SAN FRANCISCO, May 7, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financi
NEW YORK, May 7, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been f
New York, New York--(Newsfile Corp. - May 5, 2026) - WHY: Rosen Law Firm, a global investor rights l
Nektar Therapeutics (NASDAQ: NKTR) rose on positive results for alopecia treatment. Other top gainer
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is estimated to report earnings for it
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings
Companies Reporting Before The Bell • Warner Music Gr (NASDAQ:WMG) is likely to report quarterly ea
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earn
On Friday, 469 companies hit new 52-week lows.
On Thursday, 175 stocks hit new 52-week lows.
On Monday, 198 companies hit new 52-week lows.
Thursday's session saw 337 companies set new 52-week lows.
On Friday, 497 companies set new 52-week lows.
On Wednesday, 116 companies set new 52-week lows.
On Friday, 135 companies reached new 52-week lows.